These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 19857995

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.
    Reiser M, Hinrichsen H, Benhamou Y, Reesink HW, Wedemeyer H, Avendano C, Riba N, Yong CL, Nehmiz G, Steinmann GG.
    Hepatology; 2005 Apr; 41(4):832-5. PubMed ID: 15732092
    [Abstract] [Full Text] [Related]

  • 3. Telaprevir.
    Prescrire Int; 2012 Apr; 21(126):93-6. PubMed ID: 22515133
    [Abstract] [Full Text] [Related]

  • 4. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.
    Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, Füller C, Perner D, Zeuzem S, Sarrazin C.
    J Clin Virol; 2011 Dec; 52(4):321-7. PubMed ID: 21924672
    [Abstract] [Full Text] [Related]

  • 5. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S, Solas C, Motte A, Moreau J, Borentain P, Mokhtari S, Botta-Fridlund D, Dhiver C, Portal I, Ruiz JM, Ravaux I, Bregigeon S, Poizot-Martin I, Stein A, Gérolami R, Brouqui P, Tamalet C, Colson P.
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [Abstract] [Full Text] [Related]

  • 6. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
    Matthews SJ, Lancaster JW.
    Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
    [Abstract] [Full Text] [Related]

  • 7. Telaprevir: hope on the horizon, getting closer.
    Weisberg IS, Jacobson IM.
    Clin Liver Dis; 2009 Aug; 13(3):441-52. PubMed ID: 19628160
    [Abstract] [Full Text] [Related]

  • 8. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
    Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL.
    J Infect Dis; 2008 Sep 15; 198(6):800-7. PubMed ID: 18637752
    [Abstract] [Full Text] [Related]

  • 9. Conservation of hepatitis C virus nonstructural protein 3 amino acid sequence in viral isolates during liver transplantation.
    Mello IM, Thumann C, Schvoerer E, Soulier E, Pinho JR, Silvestre DA, Queiroz AT, Wolf P, Baumert TF, Keller FS, Pereira CA.
    J Viral Hepat; 2009 Oct 15; 16(10):732-7. PubMed ID: 19486468
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
    Marks KM, Jacobson IM.
    Antivir Ther; 2012 Oct 15; 17(6 Pt B):1119-31. PubMed ID: 23188750
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Kobayashi M, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2006 Jan 15; 78(1):83-90. PubMed ID: 16299715
    [Abstract] [Full Text] [Related]

  • 17. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C.
    Moucari R, Forestier N, Larrey D, Guyader D, Couzigou P, Benhamou Y, Voitot H, Vidaud M, Seiwert S, Bradford B, Zeuzem S, Marcellin P.
    Gut; 2010 Dec 15; 59(12):1694-8. PubMed ID: 20861007
    [Abstract] [Full Text] [Related]

  • 18. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient.
    Cubero M, Esteban JI, Otero T, Sauleda S, Bes M, Esteban R, Guardia J, Quer J.
    Virology; 2008 Jan 20; 370(2):237-45. PubMed ID: 18006035
    [Abstract] [Full Text] [Related]

  • 19. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H, Enomoto H, Kishima Y, Yamamoto M, Yoshida K, Okuda Y, Hirotani T, Kuroda T, Ito H, Matsuda M, Terabayashi M, Noguchi S, Kawase I, Nakamura H.
    Hepatogastroenterology; 2003 Jan 20; 50(54):2112-6. PubMed ID: 14696476
    [Abstract] [Full Text] [Related]

  • 20. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
    Vicenti I, Rosi A, Saladini F, Meini G, Pippi F, Rossetti B, Sidella L, Di Giambenedetto S, Almi P, De Luca A, Caudai C, Zazzi M.
    J Antimicrob Chemother; 2012 Apr 20; 67(4):984-7. PubMed ID: 22258932
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.